Postoperative Pembrolizumab for the Patients Who Have Solid Predominant or Micropapillary Lung Adenocarcinoma With Pathologic Stage I and Primary Tumor Than 4 cm
Clinical trial NCT03254004 · UNKNOWN
Trial details
- NCT number
- NCT03254004
- Sponsor
- Samsung Medical Center
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-08
- Primary completion
- 2021-03-30
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.